Takeda's Weber: ‘Everything Relies On Our Ability To Deliver Innovative Medicines’

With the formal completion of its huge acquisition of Shire now just a day away, some eight months after it was first announced, Takeda CEO presses home what he sees as the key priorities and benefits of the combined operation - but the real work to realize these is just beginning.

Christophe Weber
Takeda's Weber A Day Away From Realizing Shire Dream • Source: Scrip

A day before current Shire PLC employees globally get their new takeda.com email addresses, the acquisition’s most public champion Christophe Weber said he is “excited and confident” about the combined company’s future and Takeda Pharmaceutical Co. Ltd.’s transformation into what he sees as “a global, values-based, R&D-driven biopharmaceutical leader.”

The Japanese firm’s president and CEO told a Tokyo press conference on Jan. 7 that innovation and focus would be...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.